Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

October 16, 2006

Primary Completion Date

March 20, 2007

Study Completion Date

March 20, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GSK716155 subcutaneous injections

GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.

Trial Locations (6)

27560

GSK Investigational Site, Morrisville

32809

GSK Investigational Site, Orlando

33025

GSK Investigational Site, Miramar

78229

GSK Investigational Site, San Antonio

90806

GSK Investigational Site, Long Beach

94598

GSK Investigational Site, Walnut Creek

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY